 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 09/19/2008 | | | | Nymox NX-1207 Data Presented at American Urological Association Meetings in San Diego and Santa Ana Pueblo, New Mexico
topic: R&D: BPH (enlarged prostate) Treatments
September 19, 2008: Nymox is pleased to announce two separate presentations of new data by independent
clinical investigators involved in U.S. clinical trials of NX-1207, Nymox's investigational drug for
benign prostatic hyperplasia (BPH). |
| 09/16/2008 | | | | Clinical Trial Results for NX-1207 to be Presented at Second AUA Meeting in San Diego on September 18
topic: R&D: BPH (enlarged prostate) Treatments
September 16, 2008: Nymox is pleased to announce that a presentation of clinical trial data from the most
recently completed clinical studies of NX-1207, the Company’s drug in development for benign
prostatic hyperplasia (BPH) will be made by Dr. Pat Hezmall of Arlington, Texas at the 87th Annual
Meeting of the South Central Section of the American Urological Association Meeting on
September 18 in San Diego, California. |
| 09/11/2008 | | | | Clinical Trial Investigators To Present New Data Next Week on Nymox’s NX-1207 For Benign Prostatic Hyperplasia
topic: R&D: BPH (enlarged prostate) Treatments
September 11, 2008: Nymox announces that detailed new peer-reviewed data from the most recently completed clinical studies of NX-1207, the Company’s drug in development for benign
prostatic hyperplasia (BPH) will be presented at the Northeastern Section of the American Urological Association Meeting on September 18 in Santa Ana Pueblo, New Mexico. The
Nymox investigational drug has entered Phase 3 development. |
| 08/13/2008 | | | | Nymox Reports Second Quarter 2008 Financial Results
topic: Financial
August 13, 2008: Nymox Pharmaceutical Corporation (NASDAQ:
NYMX) announced today its financial results for the second quarter of 2008. |
| 08/01/2008 | | | | New Long-Term Prospective Study of Statin Drugs Confirms Utility To Reduce Risk of Dementia and Memory Loss
topic: Statins and Alzheimer's Disease
August 1, 2008: An important new study has found that people who take statin drugs were about half as likely to develop dementia or clinically significant cognitive impairment as those who did not use statins. Nymox holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of Alzheimer’s disease. |
| 07/29/2008 | | | | New Data on Nymox BPH Drug To Be Presented at American Urological Association Meeting in Monterey October 26-30
topic: R&D: BPH (enlarged prostate) Treatments
July 29, 2008: Nymox today announced that new clinical trial data concerning the safety and efficacy of the Company’s NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the Annual Meeting of the Western Section of the American Urological Association Meeting being held in Monterey, CA from October 26 to 30, 2008. |
| 07/17/2008 | | | | Nymox’s NicAlert™ Gains Acceptance in Clinical Trials and Research Studies
topic: Tobacco Exposure Tests
July 17, 2008: Nymox's NicAlert™ product has gained acceptance as an important tool in research studies and clinical trials where it is important to know the level of tobacco use or exposure among participants. |
| 07/16/2008 | | | | Almost 50% of Americans Exposed to Second-Hand Smoke According to New Report From Centers for Disease Control
topic: Tobacco Exposure Tests
July 16, 2008: Nymox offers TobacAlert™, an easy-to-use test for second-hand smoke exposure that requires no special equipment or training and can be used for at home or at the workplace. According to a newly published report by the Centers for Disease Control, despite public smoking bans, second-hand smoke exposure remains an important public health problem. Nearly half of nonsmoking Americans had detectable levels of cotinine, a biochemical marker of second-hand smoke exposure. Children aged 4-11 years had the highest percentage exposure (60.5%), even though only 10.2% of the households had self-reported second-hand smoke exposure at home. |
| 07/10/2008 | | | | BPH: A Major Challenge for Men’s Healthcare - Nymox's Innovative Treatment for BPH Enters Phase 3
topic: R&D: BPH (enlarged prostate) Treatments
July 10, 2008: Nymox has developed an innovative new treatment for BPH, NX-1207, which has now entered Phase 3, the final stage of drug testing before applying for FDA approval. |
| 06/24/2008 | | | | Independent Clinical Trial Investigators To Present New Data on Nymox’s NX-1207 Drug in Development For Benign Prostatic Hyperplasia
topic: R&D: BPH (enlarged prostate) Treatments
June 24, 2008: Nymox is pleased to announce that detailed new peer-reviewed data from the most recently completed clinical studies of NX-1207, the Company’s drug in development for benign prostatic hyperplasia (BPH) will be presented at several upcoming meetings of the American Urological Association to be held in Chicago, San Diego and Santa Ana Pueblo. |
|